Roth Capital Begins Coverage on Juniper Pharmaceuticals (JNP)
Roth Capital began coverage on shares of Juniper Pharmaceuticals (NASDAQ:JNP) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $12.00 price target on the specialty pharmaceutical company’s stock.
A number of other research firms also recently weighed in on JNP. HC Wainwright reissued a neutral rating on shares of Juniper Pharmaceuticals in a report on Monday, November 6th. ValuEngine raised Juniper Pharmaceuticals from a hold rating to a buy rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $23.00.
Juniper Pharmaceuticals (NASDAQ JNP) opened at $5.35 on Tuesday. Juniper Pharmaceuticals has a 1-year low of $3.65 and a 1-year high of $6.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68. The firm has a market capitalization of $59.10, a PE ratio of 8.52 and a beta of 0.04.
A number of hedge funds have recently bought and sold shares of JNP. Goldman Sachs Group Inc. increased its position in Juniper Pharmaceuticals by 3.4% in the second quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock worth $110,000 after buying an additional 715 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Juniper Pharmaceuticals by 1.9% in the second quarter. Dimensional Fund Advisors LP now owns 72,875 shares of the specialty pharmaceutical company’s stock worth $368,000 after buying an additional 1,344 shares in the last quarter. Algert Global LLC increased its position in Juniper Pharmaceuticals by 20.4% in the third quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock worth $658,000 after buying an additional 24,530 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in Juniper Pharmaceuticals in the third quarter worth about $129,000. Finally, Nationwide Fund Advisors increased its position in Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 55,000 shares in the last quarter. 36.39% of the stock is currently owned by institutional investors.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.